Key result
Two novel CD36 splicing site mutations were identified, with the c.430 -1G>C mutation present in 10.91% of CD36 deficient individuals compared to 1.35% of random individuals in the Guangxi population.
Observational (n=406)
Two novel CD36 splicing site mutations (c.430 -1G>C and c.1006 +2T>G) were identified as causes of CD36 deficiency in the Chinese Guangxi population.
Supports targeted genetic testing in Guangxi CD36 deficiency; leaves open validation and cardiovascular outcome studies.
OBJECTIVE: To study two novel CD36 gene mutations at the CD36 splicing sites found in Guangxi population, as well as the molecular basis and population incidence of them. METHODS: DNA sequencing and cDNA clonal sequencing were used to detect CD36 exon sequence and the protein coding region sequence of CD36 mRNA for 2 CD36 deficient individuals (HHC and WGM) found in Guangxi population. Eukaryotic expression cell lines were established for the discovery of CD36 mRNA abnormal transcripts and Western blot assay was used to verify the effect of abnormal CD36 mRNA transcripts on CD36 expression. A DNA PCR-SSP genotyping method was established for the two CD36 novel mutations, and the population distribution was investigated among 110 CD36 deficient individuals in Guangxi region and 296 random individuals in Guangxi population. RESULTS: Novel mutation of c.430 -1G>C was found at the CD36 splicing site in HHC and WGM individuals, and novel mutation of c.1006 +2T>G at the CD36 splicing site was also found in the WGM individual. CD36 cDNA clonal sequencing showed that CD36 c.430 -1G>C could lead to the production of the two CD36 mRNA transcript variants: c.429_430ins［430-17_430-2;C］(p.Ala144fsTer1) and c.430_609del(p.Ala144_Pro203del)(GenBank:HM 217023.1); and CD36 c.1006 +2T>G could lead to the production of CD36 mRNA transcript variant of c.819_1006 del (p.Ser274GlufsTer16) (GenBank: HM217025.1). It was verified that all the three transcript variants could lead to CD36 deficiency by establishment of eukaryotic expression cell lines and Western blot assay. A study of the population incidence of two novel CD36 splicing site mutations found showed that in 110 CD36 deficient individuals and in 296 random individuals in Guangxi region, the mutation rate of CD36 c.430 -1G>C was 10.91% (12/110) and 1.35% (4/296), respectively, while CD36 c.1006 +2T>G was 2.73% (3/110) and 0 (0/296), respectively. CONCLUSION: This study identifies two novel CD36 mutations at CD36 splicing site, and preliminary clarified their molecular basis for the CD36 deficiency and the distribution characteristics in Guangxi population as well. It provides an experimental and theoretical basis for studying the molecular mechanism and characteristics of CD36 deficiency in Chinese population.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) conducted an observational in CD36 deficiency (n=406). CD36 gene splicing site mutations vs. Random individuals was evaluated on Mutation rate of CD36 c.430 -1G>C. Two novel CD36 splicing site mutations were identified, with the c.430 -1G>C mutation present in 10.91% of CD36 deficient individuals compared to 1.35% of random individuals in the Guangxi population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: